T Cell News and Research

Latest T Cell News and Research

How does SARS-CoV-2 cause lymphopenia when T cells barely express ACE-2 receptors?

Researchers reveal both direct and indirect mechanisms of SARS-CoV-2-induced lymphopenia, highlighting the role of CD147 and alternative viral entry routes into T cells.

8 Jul 2024

New hope for solid tumors with enhanced CAR-T cells

A promising therapy that treats blood cancers by harnessing the power of the immune system to target and destroy cancer cells could now treat solid tumors more efficiently. Thanks to a recent study published in Molecular Therapy – Methods & Clinical Development from Dan Cappabianca and Krishanu Saha at the Wisconsin Institute for Discovery, Chimeric Antigen Receptor (CAR) T-cell therapy can be improved by altering the conditions the T cells are grown in. And it was all discovered by chance.

3 Jul 2024

Whole genome sequencing can improve clinical care of childhood cancer

Whole genome sequencing has improved clinical care of some children with cancer in England by informing individual patient care.

2 Jul 2024

Early detection of aggressive multiple myeloma through molecular analysis

Multiple myeloma is one of the most common forms of cancer of the immune cells in the bone marrow. It is considered incurable.

1 Jul 2024

Regulatory T cells exist as large, mobile population that travels through body to repair damaged tissue

Researchers investigated populations of regulatory T cells, a type of white blood cell, in various tissues.

1 Jul 2024

Lenacapavir: A breakthrough in long-acting HIV prevention for cisgender women

The injectable antiretroviral drug lenacapavir was safe and 100% effective as long-acting HIV pre-exposure prophylaxis (PrEP) among cisgender women in a Phase 3 clinical trial, according to top-line findings released by Gilead Sciences, Inc., the study sponsor.

26 Jun 2024

Enhancing adoptive T-cell therapy with nanowire innovation

Adoptive T-cell therapy has revolutionized medicine. A patient's T-cells - a type of white blood cell that is part of the body's immune system - are extracted and modified in a lab and then infused back into the body, to seek and destroy infection, or cancer cells.

24 Jun 2024

Artificial variants of Withanolides act highly specifically against leukemia cells

Nightshade plants produce a diverse array of compounds with therapeutic potential. Researchers at CeMM have now identified an artificial variant inspired by the Withanolides group that acts highly specifically against leukemia cells.

21 Jun 2024

Research finds stem-like T cells are associated with pathogenesis in ulcerative colitis

Researchers investigated whether stem-like T lymphocytes are involved in ulcerative colitis pathogenesis.

21 Jun 2024

JAK inhibitor ruxolitinib enhances immunotherapy in Hodgkin lymphoma patients

Checkpoint inhibitor therapies can be thought of as the molecular "brake release" for the immune system.

20 Jun 2024

Non-chemotherapy treatment regimen achieves full remission in aggressive B-cell lymphoma

Researchers at the National Institutes of Health (NIH) have developed a non-chemotherapy treatment regimen that is achieving full remissions for some people with aggressive B-cell lymphoma that has come back or is no longer responding to standard treatments.

19 Jun 2024

At-home antibody tests could drive higher COVID-19 booster rates, new research finds

The feasibility and benefits of lateral flow assay (LFA)-based antibody tests for detecting inadequate COVID-19 immunity.

17 Jun 2024

Case study sheds light on CAR-T therapy-related secondary cancers

A new detailed analysis of a patient's second cancer after receiving CAR-T therapy for the initial cancer provides rare but important insights intended to offer helpful guidance for oncologists and pathologists about the clinical presentation and pathologic features involved in a CAR-T related second cancer.

13 Jun 2024

Targeting basophils to revitalize cytotoxic T-cells in tumor microenvironment

The ecosystem that surrounds a tumor, also known as the tumor microenvironment, includes immune cells, tissues, blood vessels and other cells that interact with each other and with the tumor.

13 Jun 2024

Stanford study finds low risk of secondary blood cancers after CAR-T cell therapy

A large study by researchers at Stanford Medicine has found that the risk of secondary blood cancers after CAR-T cell therapy - a cell-based cancer treatment that exploded on the scene in 2017 as a treatment for intractable blood cancers - is low, despite a Food and Drug Administration warning.

12 Jun 2024

Enhancing CAR-T cell therapy with biodegradable scaffolds

CAR-T cell therapies are transforming the treatment of previously incurable blood cancers. Six approved CAR-T products have been administered to more than 20,000 people, and more than 500 clinical trials are underway.

12 Jun 2024

First-in-human trial shows safety and efficacy of CAR T cell therapy for advanced prostate cancer

Treating prostate cancer with immunotherapy is currently difficult to do. But results from a first in-human phase 1 trial using a chimeric antigen receptor (CAR) T cell therapy developed by researchers from City of Hope, one of the largest cancer research and treatment organizations in the United States, showed that patients with advanced prostate cancer can be treated safely with the cellular immunotherapy with promising therapeutic activity, according to the phase 1 trial study published today in Nature Medicine.

12 Jun 2024